Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report)’s share price rose 1.8% on Wednesday . The stock traded as high as $9.97 and last traded at $9.97. Approximately 514 shares traded hands during trading, a decline of 87% from the average daily volume of 3,939 shares. The stock had previously closed at $9.80.
Clinuvel Pharmaceuticals Stock Performance
The company’s 50 day moving average price is $9.53 and its two-hundred day moving average price is $10.19.
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Further Reading
- Five stocks we like better than Clinuvel Pharmaceuticals
- What Investors Need to Know About Upcoming IPOs
- AMD is Down 35%. Now is the Time to Buy the Dip
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Amazon Stands Tall: New Highs Are in Sight
- What is a SEC Filing?
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
